Compass TherapeuticsCMPX
Market Cap: $197M
About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
Employees: 32
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
5% more funds holding
Funds holding: 78 [Q1] → 82 (+4) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1.35% less ownership
Funds ownership: 68.84% [Q1] → 67.49% (-1.35%) [Q2]
50% less capital invested
Capital invested by funds: $188M [Q1] → $93.4M (-$94.1M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 599%upside $10 | Buy Reiterated | 12 Aug 2024 |
Wedbush Robert Driscoll 61% 1-year accuracy 41 / 67 met price target | 459%upside $8 | Outperform Reiterated | 7 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 599%upside $10 | Buy Reiterated | 6 Aug 2024 |